Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Dec-23
- 19-Sep-24
- 17-Oct-24
- 14-Nov-24
- 21-Nov-24
Select bar for recommendation details.
Recommendations | 21-Nov-24 | |
---|---|---|
Buy | 8 | |
Outperform | 15 | |
Hold | 7 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 27 analysts offering 12 month price targets for Biomarin Pharmaceutical Inc have a median target of 94.00, with a high estimate of 127.00 and a low estimate of 65.00. The median estimate represents a 46.28% increase from the last price of 64.26.
High | 97.6% | 127.00 |
Med | 46.3% | 94.00 |
Low | 1.2% | 65.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate | +72.53% |
Average growth rate | +16.00% |
More ▼
Revenue history & estimates in USD
Average growth rate | +6.51% |
Average growth rate | +9.34% |
More ▼